| 名稱(chēng) | PD-L1 aAPC Cell IO細(xì)胞株 |
| 型號(hào) | CBP74164 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | PD-L1 aAPC Cell |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74164PD-L1 aAPC Cell IO細(xì)胞株
- 詳細(xì)內(nèi)容
| CBP74164 | |
| I. Background | |
| The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. | |
| II. Introduction | |
| Expressed gene: | PDL1 |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+200ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose Response of Blocking Antibodies in PD-1/OX40 Dual Effector Reporter Cells (C22) With PD-L1 aAPC Cells. | |
會(huì)員_a.png)